PREFILLED SYRINGE: AVAILABLE!

BILLING AND CODING GUIDE

SHINGRIX
(ZOSTER VACCINE RECOMBINANT, ADJUVANTED)

This guide is intended to provide billing and coding information that may be useful for reimbursement of SHINGRIX. It is not intended to serve as comprehensive training for medical billing and coding, nor is it intended to direct the use of SHINGRIX for individual patients. Only a trained medical professional using professional judgment and clinical skills can make an informed decision about when to administer SHINGRIX.

The FDA approved SHINGRIX in a prefilled syringe presentation on July 16, 2025. The prefilled syringe eliminates the need for reconstitution, providing a convenient option.[1]



Please review the NDCs below to accurately submit claims for the SHINGRIX prefilled syringe presentation.
Important: Activate the NDCs for the prefilled syringe presentation on or after February 2nd. Be sure to keep the NDCs for the vial and vial presentation of SHINGRIX activated until all stock is depleted.

Presentation	NDC[1,*]
Prefilled Syringe Presentation	**58160-849-52:** 10-dose carton[†] • **58160-849-43:** 0.5 mL single-dose prefilled syringe
Vial and Vial Presentation	**58160-823-11:** 10-dose carton • **58160-829-03:** 10 vials of the adjuvant suspension component • **58160-828-03:** 10 vials of lyophilized gE antigen component

NDC=National Drug Code.
*Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC.[2]
[†]The prefilled syringe is only available to order in a 10-pack.

Pack Dimensions for Prefilled Syringe	WAC for Prefilled Syringe
9.9 x 17.7 x 2 cm (350 cm^3)	$242.67 per dose

Wholesale acquisition cost (WAC) is the listed price to wholesalers and warehousing chains, not including prompt-pay, stocking, or distribution allowances, or other discounts, rebates, or chargebacks. Listed prices may not represent prices charged to other customers, including specialty distributors. WAC current as of February 2026.

Storage[1]: Store the prefilled syringe refrigerated between 2°C and 8°C (36°F and 46°F). Protect from light. Do not freeze. Discard if frozen. Please refer to the Prescribing Information for additional details.

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

- in adults aged 50 years and older.
- in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

Please see additional Important Safety Information for SHINGRIX on next page and full Prescribing Information, also available at SHINGRIXHCP.com.

These vaccine product codes and common administration codes associated with immunization using SHINGRIX are the same for both presentations

Vaccine administration codes are dependent on the services provided. Please refer to the latest edition of the Current Procedural Terminology (CPT) for appropriate administration codes, and the latest edition of International Classification of Diseases (ICD) manual for appropriate diagnosis codes.

Code Type	Code
CPT Code (Product)[3]	**90750**
CPT Code (Administration)[4]	**90471:** 1 vaccine administered **90472:** Each additional vaccine administered during same encounter
ICD-10-CM Code[5]	**Z23:** Encounter for immunization
MVX Code[6]	**SKB**
CVX Code[7]	**187***

CVX=vaccine administered; ICD-10-CM=International Classification of Disease, Tenth Revision, Clinical Modification; MVX=Manufacturers of Vaccines.
*The CDC also created CVX code 188 for "zoster vaccine, unspecified formulation" to facilitate transmission of administration data when the exact formulation of the vaccine is not known (such as when recording data from a vaccination card).

Important Safety Information (cont'd)

- In postmarketing observational studies, an increased risk of Guillain-Barré syndrome has been observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)
- Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information for SHINGRIX on previous page and full Prescribing Information, also available at SHINGRIXHCP.com.

References: 1. Prescribing Information for SHINGRIX. **2.** Office injectable guidelines. National drug code (NDC) pricing and filing tips. Humana Military. Accessed February 4, 2026. https://www.humanamilitary.com/provider/claims/injectables#nucleustabs-ee21c6fea3-item-098209c56a-tab **3.** Immunization Information Systems: CPT codes mapped to CVX codes. Centers for Disease Control and Prevention. Reviewed November 26, 2025. Accessed February 4, 2026. https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt **4.** AAP Immunization Coding Table. American Academy of Pediatrics. Updated October 2025. Accessed February 4, 2026. https://downloads.aap.org/AAP/PDF/coding_vaccine_coding_table.pdf **5.** ICD-10-CM official guidelines for coding and reporting. Centers for Medicare & Medicaid Services and the National Center for Health Statistics. Updated April 1, 2024. Accessed February 4, 2026. https://www.cms.gov/files/document/fy-2024-icd-10-cm-coding-guidelines-updated-02/01/2024.pdf **6.** Immunization Information Systems: IIS: HL7 standard code set MVX – manufacturers of vaccines. Centers for Disease Control and Prevention. Reviewed November 26, 2025. Accessed February 4, 2026. https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=mvx **7.** Immunization Information Systems: Current HL7 standard code set CVX -- vaccines administered. Centers for Disease Control and Prevention. Reviewed November 26, 2025. Accessed February 4, 2026. https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=cvx

Trademarks are property of their respective owners.

©2026 GSK or licensor.
PMUS-SGXLBND260003 February 2026
Produced in USA.

SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED) | GSK